Shares of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) have been given a consensus rating of “Hold” by the eight analysts that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $8.33.

DRNA has been the topic of a number of research analyst reports. Zacks Investment Research upgraded shares of Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, July 24th. ValuEngine upgraded shares of Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, July 22nd. HC Wainwright restated a “buy” rating and issued a $5.00 price target on shares of Dicerna Pharmaceuticals in a report on Tuesday, May 23rd. Chardan Capital restated a “hold” rating on shares of Dicerna Pharmaceuticals in a report on Monday. Finally, Cowen and Company restated a “buy” rating on shares of Dicerna Pharmaceuticals in a report on Tuesday, May 9th.

Dicerna Pharmaceuticals (NASDAQ:DRNA) traded down 3.90% during mid-day trading on Tuesday, reaching $3.20. 72,827 shares of the company’s stock traded hands. The company’s market cap is $66.70 million. The stock has a 50 day moving average of $3.48 and a 200 day moving average of $3.11. Dicerna Pharmaceuticals has a 12-month low of $2.42 and a 12-month high of $6.10.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its quarterly earnings data on Thursday, August 10th. The biopharmaceutical company reported ($1.15) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.61) by $0.54. Dicerna Pharmaceuticals had a negative net margin of 8,474.12% and a negative return on equity of 140.08%. The firm had revenue of $0.25 million for the quarter, compared to the consensus estimate of $0.08 million. During the same quarter last year, the firm earned ($0.75) EPS. The company’s revenue was up 2400.0% on a year-over-year basis. On average, equities research analysts predict that Dicerna Pharmaceuticals will post ($2.39) earnings per share for the current fiscal year.

WARNING: “Dicerna Pharmaceuticals, Inc. (DRNA) Receives Consensus Recommendation of “Hold” from Brokerages” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/15/dicerna-pharmaceuticals-inc-drna-receives-consensus-recommendation-of-hold-from-brokerages.html.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Sabby Management LLC boosted its position in Dicerna Pharmaceuticals by 100.0% in the first quarter. Sabby Management LLC now owns 200,000 shares of the biopharmaceutical company’s stock worth $680,000 after buying an additional 100,000 shares during the last quarter. Renaissance Technologies LLC boosted its position in Dicerna Pharmaceuticals by 26.1% in the fourth quarter. Renaissance Technologies LLC now owns 408,682 shares of the biopharmaceutical company’s stock worth $1,177,000 after buying an additional 84,682 shares during the last quarter. Paloma Partners Management Co boosted its position in Dicerna Pharmaceuticals by 49.7% in the first quarter. Paloma Partners Management Co now owns 160,000 shares of the biopharmaceutical company’s stock worth $544,000 after buying an additional 53,131 shares during the last quarter. UBS Group AG boosted its position in Dicerna Pharmaceuticals by 0.6% in the first quarter. UBS Group AG now owns 284,645 shares of the biopharmaceutical company’s stock worth $968,000 after buying an additional 1,599 shares during the last quarter. Finally, Bourgeon Capital Management LLC raised its stake in Dicerna Pharmaceuticals by 188.9% in the second quarter. Bourgeon Capital Management LLC now owns 39,000 shares of the biopharmaceutical company’s stock worth $124,000 after buying an additional 25,500 shares during the period. Hedge funds and other institutional investors own 56.05% of the company’s stock.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Analyst Recommendations for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.